ReviewInternational journal of nanomedicine2026
Gold Nanoplatforms for Phenotypic Reprogramming and Closed-Loop Theranostics of Cancer Stem Cells.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional physical interventions, including static photothermal ablation, frequently fail to eradicate cancer stem cells (CSCs) and instead induce sublethal stress that promotes therapeutic resistance. To address this translational challenge, this review establishes a comprehensive framework utilizing engineered gold nanoplatforms to advance the treatment strategy from non-specific cytotoxicity toward mechanism-driven phenotypic reprogramming. We outline how stimuli-responsive surface functionalization helps resolve the size-permeability paradox to secure precise intracellular access. Upon internalization, these platforms suppress intrinsic defenses by intercepting morphogenic pathways, inducing mesenchymal-to-epithelial transitions, and disrupting the bioenergetic dependence of multidrug resistance. Following this phenotypic stabilization, gold nanostructures catalyze targeted cell death via ferroptotic redox disruption and dual-metabolic blockade, alongside the immunological remodeling of the tumor microenvironment. Ultimately, by integrating real-time metabolic feedback with macroscopic surveillance, this strategy highlights the potential of gold nanoplatforms as adaptive, responsive systems to achieve precision therapy and overcome CSC-driven relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.